Bifidobacterium longum CCFM1077 Attenuates Hyperlipidemia by Modulating the Gut Microbiota Composition and Fecal Metabolites:A Randomized,Double-Blind,Placebo-Controlled Clinical Trial  

作　　者：Chuanqi Chu Jinchi Jiang Leilei Yu Yiwen Li Songli Zhang Wei Zhou Qun Wang Jianxin Zhao Qixiao Zhai Fengwei Tian Wei Chen 

机构地区：[1]State Key Laboratory of Food Science and Resources,Jiangnan University,Wuxi 214122,China [2]School of Food Science and Technology,Jiangnan University,Wuxi 214122,China [3]National Engineering Research Center for Functional Food,Jiangnan University,Wuxi 214122,China [4]College of Food Science and Light Industry,Nanjing Tech University,Nanjing 211816,China [5]Yancheng Tinghu District People’s Hospital,Yancheng 224002,China [6]Department of Food Science and Technology,the University of Georgia,Athens,GA 30602,USA

出　　处：《Engineering》2023年第9期193-205,共13页工程（英文）

基　　金：supported by the Natural Science Foundation of Jiangsu Province(BK20220155 and BE2021623);the National Natural Science Foundation of China(32021005,U1903205,and 32001665);the Key Scientific and Technological Research Projects in the Key Areas of the Xinjiang Production and Construction Corps(2018AB010)。

摘　　要：An increasing number of studies have indicated that gut microbiota and its metabolites are crucial in the development of hyperlipidemia.Bifidobacterium longum(B.longum)CCFM1077 has been shown to have lipid-lowering effects in animals.This study aimed to evaluate the potential of B.longum CCFM1077 in lowering the lipid levels in patients with hyperlipidemia and investigate the effect of this bacterium on serum lipid abnormalities,gut microbiota,and fecal metabolites in these patients.This study was a six-week,randomized,double-blind,and placebo-controlled pilot clinical trial.Subjects with hyperlipidemia(N=62)were randomly assigned to receive placebo(N=31)or B.longum CCFM1077(1×1010colony-forming units(CFUs)per day;N=31).Serum lipid levels including total cholesterol(TC),lowdensity lipoprotein cholesterol(LDL-C),total triglyceride(TG),and high-density lipoprotein cholesterol(HDL-C)were examined at the baseline and interventio nal endpoints.Changes in the gut microbiota composition and diversity were measured based on 16S ribosomal RNA(rRNA)sequencing of the V3-V4region at the end of the intervention period.Non-targeted metabolomics of the feces was performed using ultra-performance liquid chromatography(UPLC)-Q-Exactive Orbitrap/mass spectrometer.Oral administration of B.longum CCFM1077 for six weeks significantly decreased the serum levels of TC(p<0.01)and LDL-C(p<0.01)in patients with hyperlipidemia.B.longum CCFM1077 treatment markedly increased gut microbiota diversity and the relative abundance of anti-obesity-related genera,including Lactobacillus,Butyricicoccus,Bifidobacterium,and Blautia,whereas it decreased the relative abundance of obesity-related genera,including Alistipes,Megamonas,and Catenibacterium.Additionally,some key metabolites(bile acids(BAs),biotin,and caffeine)and their corresponding metabolic pathways(primary BA biosynthesis,and taurine and hypotaurine,biotin,purine,and caffeine metabolisms)were enriched by B.longum CCFM1077,and thus it may lower lipid levels.B.longum CCFM1077 is a probiotic

关 键 词：PROBIOTICS Bifidobacterium longum HYPERLIPIDEMIA Gut microbiota Fecal metabolites Bile acid(BA) 

分 类 号：R589.2[医药卫生—内分泌] TS201.3[医药卫生—内科学]